Abbott Laboratories logo

ABT - Abbott Laboratories Share Price

$121.58 -0.8  -0.7%

Last Trade - 25/02/21

Large Cap
Market Cap £153.70bn
Enterprise Value £162.14bn
Revenue £24.70bn
Position in Universe 42nd / 6718
Unlock ABT Revenue
Relative Strength (%)
1m +1.26%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -5.41%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
20,405 20,853 27,390 30,578 31,904 34,608 38,623 39,676 +11.1%
+47.5 -58.9 +60.9 +28.2 +40.3 +17.7 +76.3 +5.20
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, AbbottLaboratories revenues increased 8% to $34.61B. Net incomebefore extraordinary items increased 25% to $4.5B. Revenuesreflect Diagnostics Products segment increase of 40% to$10.81B, Nutritionals Products segment increase of 3% to$7.65B, Other segment increase of 16% to $66M, UnitedStates segment increase of 14% to $13.02B, All otherCountries segment increase of 9% to $12.58B.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ABT
Graphical History


ABT Revenue Unlock ABT Revenue

Net Income

ABT Net Income Unlock ABT Revenue

Normalised EPS

ABT Normalised EPS Unlock ABT Revenue

PE Ratio Range

ABT PE Ratio Range Unlock ABT Revenue

Dividend Yield Range

ABT Dividend Yield Range Unlock ABT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ABT EPS Forecasts Unlock ABT Revenue
Profile Summary

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Company focuses on cardiovascular, diabetes care, diagnostics, neuromodulation, nutrition and medicine. It offers products, including FreeStyle, PediaSure, Pedialyte, Similac, EleCare, ZonePerfect, Juven, Ensure and Glucerna. The Company’s products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. The cardiovascular's products include Portico, MitraClip, Dilatation Catheter, among others. The diagnostics products include IntelliFISH, Vysis ALK, STARLIMS, PathVysion, AlinIQ, among others.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated March 6, 1900
Public Since March 1, 1937
No. of Shareholders: 37,450
No. of Employees: 109,000
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index FTSE Global 100, S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange New York Stock Exchange
Shares in Issue 1,771,529,358
Free Float (0.0%)
Eligible for
ABT Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ABT
Upcoming Events for ABT
Wednesday 14th April, 2021 Estimate
Q1 2021 Abbott Laboratories Earnings Release
Frequently Asked Questions for Abbott Laboratories
What is the Abbott Laboratories share price?

As of 25/02/21, shares in Abbott Laboratories are trading at $121.58, giving the company a market capitalisation of £153.70bn. This share price information is delayed by 15 minutes.

How has the Abbott Laboratories share price performed this year?

Shares in Abbott Laboratories are currently trading at $121.58 and the price has moved by 49.43% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Abbott Laboratories price has moved by 13.4% over the past year.

What are the analyst and broker recommendations for Abbott Laboratories?

Of the analysts with advisory recommendations for Abbott Laboratories, there are there are currently 8 "buy" , 4 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Abbott Laboratories is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Abbott Laboratories next release its financial results?

Abbott Laboratories is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Abbott Laboratories dividend yield?

The Abbott Laboratories dividend yield is 1.18% based on the trailing twelve month period.

Does Abbott Laboratories pay a dividend?

Last year, Abbott Laboratories paid a total dividend of 1.44, and it currently has a trailing dividend yield of 1.18%. Looking ahead, shares in Abbott Laboratories are due to go ex-dividend on 2021-04-14 and the next dividend pay date is 2021-05-17.

When does Abbott Laboratories next pay dividends?

Abbott Laboratories are due to go ex-dividend on 2021-04-14 and the next dividend pay date is 2021-05-17. The historic dividend yield on Abbott Laboratories shares is currently 1.18%.

How do I buy Abbott Laboratories shares?

To buy shares in Abbott Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Abbott Laboratories?

Shares in Abbott Laboratories are currently trading at $121.58, giving the company a market capitalisation of £153.70bn.

Where are Abbott Laboratories shares listed? Where are Abbott Laboratories shares listed?

Here are the trading details for Abbott Laboratories:

Country of listing: United States
Exchange: NYQ
Ticker Symbol: ABT
What kind of share is Abbott Laboratories?

Based on an overall assessment of its quality, value and momentum, Abbott Laboratories is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Abbott Laboratories share price forecast 2021?

Shares in Abbott Laboratories are currently priced at $121.58. At that level they are trading at 1.54% premium to the analyst consensus target price of 0.00.

Analysts covering Abbott Laboratories currently have a consensus Earnings Per Share (EPS) forecast of 4.402 for the next financial year.

How can I tell whether the Abbott Laboratories share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abbott Laboratories. Over the past six months, the relative strength of its shares against the market has been -2.15%. At the current price of $121.58, shares in Abbott Laboratories are trading at 15.83% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Abbott Laboratories PE Ratio?

The Abbott Laboratories PE ratio based on its reported earnings over the past 12 months is 48.7. The shares are currently trading at $121.58.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Abbott Laboratories?

Abbott Laboratories's management team is headed by:

Miles White - CHM
Roxanne Austin - IND
Robert Funck - CFO
John Capek - EVP
William Osborn - LED
Robert Alpern - IND
Sally Blount - IND
Hubert Allen - EVP
Robert Ford - PRE
Daniel Salvadori - EVP
Andrew Lane - EVP
Michelle Kumbier - IND
Lisa Earnhardt - EVP
John Ginascol - EVP
Mary Moreland - EVP
Who are the major shareholders of Abbott Laboratories?

Here are the top five shareholders of Abbott Laboratories based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.31% (147.3m shares)
Capital Research Global Investors Investment Advisor
Percentage owned: 4.88% (86.4m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.87% (86.3m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 4.03% (71.3m shares)
Capital International Investors Investment Advisor
Percentage owned: 3.03% (53.6m shares)
Similar to ABT
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.